Physician profile
Henry Park
NPI 1427219807
$4,176.62
in general payments reported to CMS, 2019-2025
38 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.45 · 2020: $12.79 · 2021: $15.08 · 2022: $386 · 2023: $618 · 2024: $1,780 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,694.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $667.34 | 2021-2025 | Briviact, Fintepla, Rystiggo |
| Novocure INC. | $532.27 | 2022-2025 | Optune, Optune Gio |
| Teva Pharmaceuticals USA, INC. | $513.05 | 2023-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $303.07 | 2023-2025 | Xcopri |
| Neurelis, INC. | $238.76 | 2024-2025 | Valtoco |
| Tanabe Pharma America, INC. | $209.32 | 2023-2025 | Radicava |
| Medtronic, INC. | $146.04 | 2024-2025 | Percept PC Brainsense, Stealthstation S8 Platform |
| Astrazeneca Pharmaceuticals LP | $139.13 | 2024-2025 | Andexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $132.04 | 2022 | |
| Lundbeck LLC | $121.78 | 2024 | Vyepti |
| Tonix Medicines, INC. | $105.40 | 2024-2025 | Zembrace Symtouch |
| Servier Pharmaceuticals LLC | $104.91 | 2024-2025 | |
| Argenx US, INC. | $99.78 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $98.89 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $70.21 | 2024-2025 | Crexont, Rytary |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $69.39 | 2023-2024 | Emgality, Reyvow |
| W. L. Gore & Associates, INC. | $57.79 | 2023-2025 | Gore Cardioform Septal Occluder |
| Chiesi USA, INC. | $51.24 | 2025 | Cleviprex |
| Merz Pharmaceuticals, LLC | $49.11 | 2024-2025 | Xeomin, Inbrija |
| Alexion Pharmaceuticals, INC. | $45.03 | 2023-2024 | Ultomiris, Soliris |
| Otsuka America Pharmaceutical, INC. | $44.54 | 2023-2024 | Nuedexta |
| Portola Pharmaceuticals, LLC | $40.16 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $35.98 | 2024-2025 | Ingrezza |
| Amylyx Pharmaceuticals, INC. | $31.45 | 2023 | Relyvrio |
| Abbvie INC. | $29.57 | 2022-2024 | |
| Ethicon US, LLC | $25.71 | 2019 | |
| Masimo Corporation | $22.69 | 2024 | Set and Rainbow Set |
| Livanova USA, INC. | $20.58 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| La Jolla Pharmaceutical Company | $19.02 | 2025 | Giapreza |
| Biogen, INC. | $18.68 | 2025 | Qalsody, Spinraza |
| Electromed, INC. | $18.22 | 2024 | Smartvest |
| Melinta Therapeutics, LLC | $17.66 | 2025 | Rezzayo |
| Irras USA, INC. | $17.57 | 2024 | |
| Kyowa Kirin, INC. | $16.65 | 2024 | Nourianz |
| Aucta Pharmaceuticals, INC. | $16.45 | 2025 | Motpoly Xr |
| Catalyst Pharmaceuticals, INC. | $16.08 | 2024 | |
| Acadia Pharmaceuticals INC | $15.69 | 2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $15.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.